

Russian Pharmaceutical Market Outlook to 2017

https://marketpublishers.com/r/R1A2F00B41DEN.html

Date: November 2013

Pages: 80

Price: US\$ 800.00 (Single User License)

ID: R1A2F00B41DEN

Abstracts

The pharmaceutical industry in Russia finally seems ready for a change. With the government adopting 'Strategy 2020' to improve the production capacity of the Russian pharma sector, pharmaceutical companies have started investing in the Russian market. As a result, the Russian pharmaceutical industry has started growing at a steady rate. In future, various factors such as increased support from the government, rise in expenditure on healthcare, and noteworthy growth in investments made by the private players will continue to boost the market.

According to our report, "Russian Pharmaceutical Market Outlook to 2017", the pharmaceutical market is anticipated to grow at a CAGR of around 11% during 2012-2017. Essentially, RNCOS' report provides an exhaustive study of the Russian pharmaceuticals market. A section has been dedicated to the industry's infrastructure which focuses on the emerging pharmaceutical clusters in Russia and the role they will play in shaping the market.

The market has been segmented as per various levels such as the state segment, the commercial segment and the parapharmaceutical segment. Subsequently, markets for these segments have been further broken down on the basis of their ATC groups. The drugs import scenario for each segment has also been provided. Moreover, major distributors of the pharmaceutical industry have been highlighted along with their respective market shares.

The report provides an insight into the clinical trial scenario and reveals that almost twice the number of clinical trials has been approved in 2012 as compared to 2011. This is indicative of the increasing government support in order to boost domestic innovation. Further, current market driving forces and roadblocks have been discussed. On the one hand, increasing support from the government can be seen as a ray of hope for providing the market a necessary boost, while on the other corruption, deep rooted at



every level, may act as a deterrent.

The report also focuses on the current regulatory reforms such as the transition to GMP standards, promotion, and procurement of pharmaceuticals which will play important roles in sculpting the market. Lastly, detailed analysis of major pharmaceutical players within Russia has been given with emphasis on strengths and weaknesses as well as the recent developments of each player.



Contents

- 1. ANALYST VIEW
- 2. RESEARCH METHODOLOGY
- 3. PHARMACEUTICAL INDUSTRY INFRASTRUCTURE OVERVIEW
- 4. PHARMACEUTICAL MARKET OUTLOOK TO 2017
- 4.1 Market Size & Growth
- 4.2 Branded and Generics Drugs
- 4.3 Commercial Drugs Market
 - 4.3.1 Revenue by Anatomical Therapeutic Chemical (ATC) Classification System
 - 4.3.2 Leading Companies
 - 4.3.3 Leading Drugs
 - 4.3.4 Drugs Import Scenario
- 4.4 State Segment
 - 4.4.1 Drug Reimbursement Program (DLO)
 - 4.4.1.1 Revenue by Anatomical Therapeutic Chemical (ATC) Classification System
 - 4.4.1.2 Leading Companies
 - 4.4.1.3 Leading Drugs
 - 4.4.1.4 Drugs Import Scenario
 - 4.4.2 Hospital Segment
 - 4.4.2.1 Revenue by Anatomical Therapeutic Chemical (ATC) Classification System
 - 4.4.2.2 Leading Companies
 - 4.4.2.3 Leading Drugs
 - 4.4.2.4 Drugs Import Scenario
- 4.5 Parapharmaceutical Market
 - 4.5.1 Nutritional Supplements Market
 - 4.5.2 Leading Companies
 - 4.5.3 Drugs Import Scenario
- 4.6 Pharmaceutical Distribution System
- 5. CLINICAL TRIALS MARKET OUTLOOK
- 6. INDUSTRY ANALYSIS
- 6.1 Market Driving Forces



- 6.1.1 Government Support for Industry Development
- 6.1.2 Higher FDI Inflows
- 6.1.3 Increasing Share of Expensive Drugs
- 6.1.4 Rise in Purchasing Power: Better Affordability
- 6.2 Industry Roadblocks

7. REGULATORY ENVIRONMENT

- 7.1 Current Reforms
- 7.2 Objective and Impact of Proposed Laws and Legislations

8. COMPETITIVE LANDSCAPE

- 8.1 Sanofi-Aventis
 - 8.1.1 Business Overview
 - 8.1.2 Product Portfolio
 - 8.1.3 Key Financials
 - 8.1.4 Strengths and Weaknesses
 - 8.1.5 Recent Developments
- 8.2 Novartis Pharma ZAO
 - 8.2.1 Business Overview
 - 8.2.2 Product Portfolio
 - 8.2.3 Key Financials
- 8.2.4 Strengths and Weaknesses
- 8.3 Roche Moscow Ltd.
 - 8.3.1 Business Overview
 - 8.3.2 Product Portfolio
 - 8.3.3 Key Financials
 - 8.3.4 Strengths and Weaknesses
 - 8.3.5 Recent Developments
- 8.4 Teva Pharmaceutical
 - 8.4.1 Business Overview
 - 8.4.2 Product Portfolio
 - 8.4.3 Key Financials
 - 8.4.4 Recent Developments
- 8.5 Pharmstandard JSC
 - 8.5.1 Business Overview
 - 8.5.2 Product Portfolio
 - 8.5.3 Strengths and Weaknesses



8.5.4 Recent Developments



List Of Figures

LIST OF FIGURES:

- Figure 4-1: Pharmaceutical Market (Trillion RUB), 2012-2017
- Figure 4-2: Pharmaceutical Market Breakup by Segment (%), 2012-2017
- Figure 4-3: Share of Branded and Generics in Pharmaceutical Market (2012)
- Figure 4-4: Commercial Drugs Market (Trillion RUB), 2012-2017
- Figure 4-5: Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Value (2011 & 2012)
- Figure 4-6: State Segment Drugs Market (Billion RUB), 2012-2017
- Figure 4-7: Disbursement under DLO Program (Billion RUB), 2011-2013
- Figure 4-8: Share of Imported & Domestic Drugs under DLO Program by Sales Value (2011-2013)
- Figure 4-9: Share of Imported & Domestic Drugs under Hospital Segment by Sales Value (2011-2013)
- Figure 4-10: Parapharmaceutical Market (Billion RUB), 2012-2017
- Figure 4-11: Nutritional Supplements Market (Billion RUB), 2011-2013
- Figure 4-12: Share of Imported & Domestic Nutritional Supplements by Sales Value (2012)
- Figure 5-1: Number of Clinical Trials Approved (2010-2012)
- Figure 5-2: Clinical Trials by Therapeutic Area (%), 2012
- Figure 5-3: Clinical Trials by Sponsor Country (%), 2012
- Figure 6-1: Share of Pharmaceuticals' Sales by Price Bracket (2011 & 2012)
- Figure 6-2: Gross National Income per Capita ('000 US\$), 2009-2012
- Figure 6-3: Global Distribution of Counterfeit Medicines (%), 2012



List Of Tables

LIST OF TABLES:

- Table 4-1: Commercial Drugs Sales Structure of ATC Groups (2012)
- Table 4-2: Leading Companies in Commercial Drugs Market by Sales (Million RUB), 2012
- Table 4-3: Leading Drugs in Commercial Drugs Market by Sales (Million RUB), 2012
- Table 4-4: Drugs Sales Structure of ATC Groups under DLO Program (2012)
- Table 4-5: Leading Companies under DLO Program by Sales (Million RUB), 2012
- Table 4-6: Leading Drugs under DLO Program by Sales (Million RUB), 2012
- Table 4-7: Drugs Sales Structure of ATC Groups under Hospital Segment (2012)
- Table 4-8: Leading Companies under Hospital Segment by Sales (Million RUB), 2012
- Table 4-9: Leading Drugs under Hospital Segment by Sales (Million RUB), 2012
- Table 4-10: Leading Companies under Nutritional Supplement Segment by Sales (Million RUB), 2012
- Table 4-11: Leading Distributors in Pharmaceutical Market by Sales (Million RUB), 2012
- Table 8-1: Sanofi-Aventis Key Financials (Million €), 2010-2012
- Table 8-2: Sanofi-Aventis Strengths & Weaknesses
- Table 8-3: Novartis Key Financials (Million US\$), 2010-2012
- Table 8-4: Novartis Strengths & Weaknesses
- Table 8-5: Pharmstandard Strengths & Weaknesses



I would like to order

Product name: Russian Pharmaceutical Market Outlook to 2017

Product link: https://marketpublishers.com/r/R1A2F00B41DEN.html

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/R1A2F00B41DEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

**All fields are required
Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms